ClinicalTrials.gg
CompletedNCT01559090Updated Mar 13, 2019Results posted

Safety and Tolerability of Intravenous Dose of MEDI-546 in Japanese Subjects With Systemic Lupus Erythematosus.

A Phase 2 interventional study of MEDI-546 and MEDI-546 in Systemic Lupus Erythematosus, sponsored by AstraZeneca. Completed at 6 sites in Japan. Open to participants aged 18 Years to 65 Years. Per ClinicalTrials.gov, last updated 2019-03-13.

Sponsored by AstraZeneca · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
17
Allocation
Non-randomized
Ages
18 Years to 65 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic — 9 open to participants now, 11 under way, 6 of them phase 3. anifrolumab · Lupus Erythematosus, Systemic.

Enrollment
17th of 20
17 · median 159
Started
2012
with 1 other
Phase 2
6 of 20
2 open now
Registered
2nd of 20
by date
Lead sponsor
15 of 20
AstraZeneca

Among the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, this one is the 17th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 2, and was the 2nd registered.

Lupus Erythematosus, Systemic

1,210 studies on the registry are indexed under Lupus Erythematosus, Systemic; 406 are open to participants now.

Browse Lupus Erythematosus, Systemic studies →

Open to participants now

9 of the 20 studies testing anifrolumab in Lupus Erythematosus, Systemic are open now, in 12 countries. Recruiting first, the newest first:

4 more — sign in →

By country, each count listing its studies:

All 9 open studies →

About anifrolumab

anifrolumab: first FDA approval 2021 (SAPHNELO), first EMA approval 2022. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 284 Lupus Erythematosus, Systemic studies recruiting now, 93 (33%) set no upper age limit and 161 (57%) stop at 75 or younger; 54 take children under 18; 33 take healthy volunteers.

This study: 18 Years to 65 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 20 studies testing anifrolumab in Lupus Erythematosus, Systemic, or all of them as a file.
02

Study summary

The purpose of this study is to assess safety, tolerability, pharmacokinetics and pharmacodynamics of MEDI-546 in Japanese SLE patients.

Read the detailed description

A phase 2, multicenter, open-label, dose-escalation study to evaluate the safety and tolerability of intravenous dose of MEDI-546, a human monoclonal antibody directed against type I interferon receptor (IFNAR), in Japanese subjects with active systemic lupus erythematosus (SLE)

03

Conditions studied

  • Systemic Lupus Erythematosus

Keywords

  • Japan
  • Phase2
  • Safety
  • Tolerability
  • Systemic Lupus Erythematosus
  • SLE, MEDI-546
04

Who can participate

Ages eligible
18 Years to 65 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Fulfils at least 4 of the 11 American College of Rheumatology (ACR) classification criteria for SLE.
  • Weight greater than or equal to 40.0 kg.
  • Diagnosis of pediatric or adult SLE with chronic disease activity requiring ongoing treatment or observation for ≥ 24 weeks prior to screening.
  • Currently receiving stable dose of oral prednisone and/or antimalarials/immunosuppressives.
  • Active moderate to severe SLE disease based on SLE disease activity score.

Exclusion criteria

Exclusion Criteria:

  • Active severe or unstable neuropsychiatric SLE.
  • Active severe SLE-driven renal disease or unstable renal disease.
  • active infection including ongoing and chronic infections.
  • Known history of a primary immunodeficiency or an underlying condition such as infection or splenectomy that predisposes the subject to infection.
  • Confirmed positive tests for or positive test for .
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
17 participants (actual)

Study arms

  • Experimental
    1

    MEDI-546 100 mg IV

    Drug: MEDI-546

  • Experimental
    2

    MEDI-546 300 mg IV

    Drug: MEDI-546

  • Experimental
    3

    MEDI-546 1000 mg IV

    Drug: MEDI-546

Interventions

  • Stage I: 100 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks

  • Stage I: 300 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 300 mg IV, multiple doses once every 4 wks for 156 wks

  • Stage I: 1000 mg IV, single dose and multiple doses once every 4 wks for 48 wks Stage II: 1000 mg IV, multiple doses once every 4 wks for 156 wks, the dose at Stage II was changed to 300 mg IV.

06

What researchers measure

Primary outcomes

  1. Overall Summary of Adverse Events

    Time frame: Stage I (up to 48 weeks)

Secondary outcomes

  1. Pharmacokinetic Parameters of MEDI-546 After Single Dose: Cmax

    Time frame: Pre-dose and within 30 minutes after end of infusion on Day 1, Days 2, 8, 15, and 22, and pre-dose on Day 29

  2. Pharmacokinetic Parameters of MEDI-546 After Single Dose: AUClast

    Time frame: Pre-dose and within 30 minutes after end of infusion on Day 1, Days 2, 8, 15, and 22, and pre-dose on Day 29

  3. Anti-drug Antibody (ADA)

    MEDI-546 antibody detection measured by electrochemiluminescence (ECL).

    Time frame: Stage I (up to Week 48)

07

Results

Posted Mar 13, 2019

Participant flow

Stage I
Participant flow — Stage I
MilestoneMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Started656
Completed433
Not completed223
Withdrew: Withdrawal by subject223
Stage II
Participant flow — Stage II
MilestoneMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Started432
Completed332
Not completed100
Withdrew: Withdrawal by subject100

Outcome measures

SecondaryPharmacokinetic Parameters of MEDI-546 After Single Dose: Cmax
Time frame:
Pre-dose and within 30 minutes after end of infusion on Day 1, Days 2, 8, 15, and 22, and pre-dose on Day 29
Reported as:
Geometric mean · ug/mL
Pharmacokinetic Parameters of MEDI-546 After Single Dose: Cmax
ug/mLMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Pharmacokinetic Parameters of MEDI-546 After Single Dose: Cmax41.1 ± 27.675.1 ± 12.5254.8 ± 20.7
PrimaryOverall Summary of Adverse Events
Time frame:
Stage I (up to 48 weeks)
Reported as:
Count of participants · Participants
Overall Summary of Adverse Events
ParticipantsMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Any AE656
Any AE of grade 3 or higher111
Any AE with outcome=death000
Any SAE223
Any AE leading to discontinuation of IP211
Any causally related AE544
Any other significant AE000
SecondaryPharmacokinetic Parameters of MEDI-546 After Single Dose: AUClast
Time frame:
Pre-dose and within 30 minutes after end of infusion on Day 1, Days 2, 8, 15, and 22, and pre-dose on Day 29
Reported as:
Geometric mean · ug.day/mL
Pharmacokinetic Parameters of MEDI-546 After Single Dose: AUClast
ug.day/mLMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Pharmacokinetic Parameters of MEDI-546 After Single Dose: AUClast221.5 ± 18.8666.5 ± 36.83151.9 ± 14.6
SecondaryAnti-drug Antibody (ADA)

MEDI-546 antibody detection measured by electrochemiluminescence (ECL).

Time frame:
Stage I (up to Week 48)
Reported as:
Count of participants · Participants
Anti-drug Antibody (ADA)
ParticipantsMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Positive111
Negative545

Adverse events

Collected over Stage I: 337 to 422 days. Non-serious events are listed at a 2% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
MEDI-546 100 mg IV0/6 (0%)2/6 (33.3%)6/6 (100%)
MEDI-546 300 mg IV0/5 (0%)2/5 (40%)5/5 (100%)
MEDI-546 1000 mg IV0/6 (0%)3/6 (50%)6/6 (100%)
Most frequent serious events
Most frequent serious events
EventMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
Systemic lupus erythematosusMusculoskeletal and connective tissue disorders0/61/51/6
CellulitisInfections and infestations0/61/50/6
LymphadenopathyBlood and lymphatic system disorders0/60/51/6
Acute abdomenGastrointestinal disorders1/60/50/6
Chest painGeneral disorders0/60/51/6
Cerebral infarctionNervous system disorders1/60/50/6
AbortionPregnancy, puerperium and perinatal conditions0/60/51/6
Most frequent other events
Showing 10 of 15
Most frequent other events
EventMEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IV
NsopharyngitisInfections and infestations3/61/54/6
Herpes zosterInfections and infestations0/62/50/6
Upper respiratory tract infectionInfections and infestations2/60/51/6
GastroenteritisInfections and infestations2/60/50/6
Abdominal pain upperGastrointestinal disorders1/61/52/6
HypertensionVascular disorders2/60/50/6
BronchitisInfections and infestations1/61/50/6
InfluenzaInfections and infestations1/61/50/6
NauseaGastrointestinal disorders0/61/51/6
HeadacheNervous system disorders1/61/51/6

Baseline characteristics

Age, Continuous
Age, Continuous(years)MEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IVTotal
Mean43 ± 1234 ± 1137 ± 1038 ± 11
Sex/Gender, Customized
Sex/Gender, Customized(male/female)MEDI-546 100 mg IVMEDI-546 300 mg IVMEDI-546 1000 mg IVTotal
Male01016
Female6461
08

Study locations

6 sites
  • Research Site
    Chiba-shi, 260-8677, Japan
  • Research Site
    Chuo-ku, 104-8560, Japan
  • Research Site
    Ota-ku, 143-8541, Japan
  • Research Site
    Sendai-shi, 980-8574, Japan
  • Research Site
    Shimotsuke-shi, 329-0498, Japan
  • Research Site
    Shinjuku-ku, 160-8582, Japan
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Apr 2012 to primary completion in Aug 2014, 27 months.

Results were first posted in Mar 2019, 4 years 6 months after primary completion.

Of 67 industry-sponsored phase 2 interventional studies under Lupus Erythematosus, Systemic, half reached primary completion within 32 months of starting (the median), counting those still running; a quarter within 25 and three quarters within 48. This study's 27 months is below that.

Counting every sponsor, half of 95 studies reached it within 36 months; a quarter within 27 and three quarters within 56.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 19, 2012
First posted
Mar 21, 2012
StartActual
Apr 20, 2012
Primary completionActual
Aug 19, 2014
CompletionActual
Feb 21, 2017
Results first posted
Mar 13, 2019
Last update
Mar 13, 2019
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Mar 13, 2019, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01559090
Lead sponsor
AstraZeneca
Collaborators
MedImmune LLC
Responsible party
Sponsor
First posted
Mar 21, 2012
Start date
Apr 20, 2012
Primary completion
Aug 19, 2014
Completion
Feb 21, 2017
Results posted
Mar 13, 2019
Last update
Mar 13, 2019

Study contacts

Roberta Weiss, MD
study director · MedImmune LLC

Oversight

Data monitoring committee
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Mar 2019. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Anifrolumab

Start the discussion